Patent portfolio

Biomarker and diagnostics portfolio

1. Prognostic and Diagnostic Glycan-based Biomarkers of Brain Damage
   • European patent No. 3283880
   • US patent No. 10,739,335
   • Canadian patent No. 2,982,503
   • Israeli patent No. 254 980
2. Non-invasive Brain Injury Diagnostic Device
   • PCT application WO/2018/154,401, has entered into national phases
   • South African patent (number pending)
   • Utility model granted in China and Australia
3. Device and Method for Detecting of Brain injury in a Subject
   • PCT application WO 2021/099677
     Australian innovation patent No. 2020104474
   • Finnish Utility model No. 13179
4. A Method for Determining a Lectin-binding Glycan Indicative To Traumatic Brain Injury
   • PCT application WO 2021/205059
   • European patent No. 4133279
5. A Method for Diagnosis of Traumatic Brain Injury
   • PCT-application WO 2023/161557
   • Finnish patent No. 130340
6. Method of Detecting Tissue Damage
   • PCT-application WO 2023/161553
   • Finnish patent No. 130428
   • Divisional Finnish patent No. 130798
7. A Hand-held Liquid Sample Collection and Testing Device
   • Finnish utility model No. 13331
   • German utility model No. 20 2023 100 246
   • Austrian utility model pending

Drug development portfolio

1. Multivalent Compounds for Use in the Treatment and Prevention of Brain Damage
   • US patent No. 9,975,846
   • Finnish patent No. 127024
   • Israeli patent No. 251407
   • European patent No. 3201173
2. Conjugates and Conjugates for Use in Preventing or Treating of Brain Damage and Neurodegenerative Diseases
   • PCT application WO 2021/038125
   • Finnish patent No. 130262

Other patents 

1. Method for Determining Coronavirus and Kit for the Same
   • PCT application WO 2021/205058
   • European patent No. 3911956